LFMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LifeMD Inc (LFMD) is not a strong buy at the moment for a long-term beginner investor. While there are positive analyst upgrades and growth in revenue, the significant drop in net income and EPS, coupled with a lack of strong trading signals or recent news catalysts, suggests a cautious approach. The technical indicators and options sentiment do not strongly favor immediate entry.
The MACD is positive at 0.097, indicating mild bullish momentum, but it is contracting. RSI at 62.56 is neutral, and moving averages are converging, suggesting no clear trend. The current price of $4.491 is near the pivot level of $4.234, with resistance at $4.889 and support at $3.579.
Gross margin improvement to 87.14%.
No significant hedge fund or insider trading activity. Lack of recent news or event-driven catalysts.
In Q4 2025, revenue increased by 3.84% YoY to $46.87M, gross margin improved to 87.14%, but net income dropped significantly by -435.72% YoY to $19.19M, and EPS fell by -392.86% YoY to 0.41.
Analysts are bullish with multiple upgrades and increased price targets. Mizuho upgraded to Outperform with a target of $8, citing growth potential in GLP-1 drugs. Freedom Capital and H.C. Wainwright raised price targets to $10, highlighting growth reacceleration and strong user-retention metrics.
